On November 6, 2025, Jefferies upgraded Insulet Corporation's stock (NASDAQ:PODD) to a "Buy" rating, setting a new price target of $400, up from $375. At the time, the stock was priced at $323.40. Insulet, a leader in insulin infusion systems, has been gaining attention for its innovative wearable insulin pumps, which provide an alternative to daily injections.
During its third-quarter 2025 earnings call, Insulet reported earnings per share of $1.24, surpassing the Zacks Consensus Estimate of $1.13. This represents a 9.73% earnings surprise and a notable increase from the $0.90 per share recorded in the same period last year. The company's consistent ability to exceed expectations highlights its strong position in the Zacks Medical - Products industry.
Insulet's revenue for the quarter ending in September 2025 reached $706.3 million, exceeding the Zacks Consensus Estimate by 4.42%. This is a significant increase from the $543.9 million reported in the same quarter the previous year. The company's strong financial performance is driven by high demand for its wearable insulin pumps, which have been well-received in the market.
The stock price of PODD reflects a 2.85% increase, or $8.96, on the day of the announcement. The stock has fluctuated between a low of $290.16 and a high of $335 during the trading day. Over the past year, PODD has reached a high of $353.50 and a low of $230.05, with a market capitalization of approximately $22.76 billion.
The earnings call, attended by analysts from major financial institutions, provided insights into Insulet's strategic direction. The company's strong performance and positive outlook have contributed to the stock's upward momentum, as highlighted by Jefferies' upgrade and increased price target.
